A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities. Simply put, the GAO report misses the mark.
Jun 9, 2015 by Linda Fishman
A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.
Dec 8, 2014 by Linda Fishman
A new report ;by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.
Health Affairs Study Gets It Wrong on 340B: Hospitals Use the Program to Help Vulnerable Patients and CommunitiesOct 6, 2014 by Linda Fishman
The 340B program accounts for only two percent of the $325 billion in annual drug purchases made in the U.S., or roughly $6.5 billion. Hospitals participating in the 340B program provided $28.4 billion in uncompensated care in 2012; in other words, four times the drug purchase amount.